First human test of new cancer pill halted early
NCT ID NCT04762602
Summary
This was an early-stage study to check the safety and find the right dose of an experimental pill called HMPL-306. It was for adults with advanced solid tumors that had a specific genetic change (IDH mutation) and had stopped responding to standard treatments. The study was terminated early, so the main goal was to understand how the drug is processed by the body and what side effects it might cause.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ISOCITRATE DEHYDROGENASE GENE MUTATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Emory University
Atlanta, Georgia, 30322, United States
-
Hospital Universitari Vall d'Hebron
Barcelona, 08035, Spain
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Hospital de la Santa creu i Sant Pau
Barcelona, 08025, Spain
-
Houston Methodist
Houston, Texas, 77030, United States
-
Sarcoma Oncology Research Center
Santa Monica, California, 90403, United States
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Thomas Jefferson University
Philadelphia, Pennsylvania, 19107, United States
-
UPMC Hillman Cancer
Pittsburgh, Pennsylvania, 15232, United States
-
University of Iowa
Iowa City, Iowa, 52242, United States
-
University of Kentucky
Lexington, Kentucky, 40536, United States
Conditions
Explore the condition pages connected to this study.